Patents Assigned to Rigshospitalet
-
Patent number: 9381243Abstract: The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.Type: GrantFiled: July 11, 2014Date of Patent: July 5, 2016Assignee: RigshospitaletInventors: Pär Johansson, Sisse Rye Ostrowski
-
Patent number: 9226984Abstract: The present invention is directed to the technical field of imaging compositions useful for diagnosing cancer and other diseases in a subject. In particular, the invention relates to a class of diagnostic compounds comprising a novel liposome composition with encapsulated metal entities such as radionuclides, for example 61Cu and 64Cu copper isotopes. The invention further relates to a novel method for loading delivery systems, such as liposome compositions, with metal entities such as radionuclides, and the use of liposomes for targeted diagnosis and treatment of a target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.Type: GrantFiled: December 14, 2011Date of Patent: January 5, 2016Assignee: Technical University of Denmark and RigshospitaletInventors: Anncatrine Luisa Petersen, Jonas Rosager Henriksen, Palle Hedengran Rasmussen, Andreas Kjær, Thomas Lars Andresen
-
Patent number: 9012154Abstract: The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement acType: GrantFiled: June 9, 2010Date of Patent: April 21, 2015Assignees: Rigshospitalet, University of CopenhagenInventors: Peter Garred, Christian Honore
-
Publication number: 20150057325Abstract: The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.Type: ApplicationFiled: March 26, 2013Publication date: February 26, 2015Applicant: RigshospitaletInventors: Pär Johansson, Sisse Rye Ostrowski
-
Patent number: 8920775Abstract: The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications.Type: GrantFiled: July 16, 2010Date of Patent: December 30, 2014Assignees: Technical University of Denmark, RigshospitaletInventors: Anncatrine Luisa Petersen, Palle Hedengran Rasmussen, Jonas Rosager Henriksen, Andreas Kjær, Thomas Lars Andresen
-
Publication number: 20140341807Abstract: There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.Type: ApplicationFiled: August 23, 2012Publication date: November 20, 2014Applicants: DANMARKS TEKNISSKE UNIVERSITET, RIGSHOSPITALETInventors: Andreas Kjaer, Ulrick Knigge, Liselotte Højgaard, Palle Rasmussen
-
Publication number: 20140272998Abstract: The present invention relates to the field of cancer-diagnostics. In particular the invention relates to a microRNA expression signature that allows discriminating skin samples of cutaneous T-cell lymphomas (CTCL) from non-malignant (inflammantory) skin samples by use of quantitative polymerase chain reaction performed on reverse transcribed miRNA. miR-155, miR-326, miR-663b, miR-203 and miR-205 are shown to be differentially expressed.Type: ApplicationFiled: July 13, 2012Publication date: September 18, 2014Applicants: LEO PHARMA A/S, COPENHAGEN UNIVERSITY, RIGSHOSPITALET, GENTOFTE HOSPITALInventors: Ulrik Ralfkiaer, Peter Hagedorn, Charlotte Busch Ahler, Carsten Geisler, Anders Woetmann, Lone Skov, Niels Feentved Odum, Elisabeth Ralfkiaer
-
Publication number: 20140120105Abstract: The present Invention relates to novel antibodies against Ficolin-3, which antibodies inhibit complement activation. The invention further relates to the use of anti-Ficolin-3 antibodies in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to nucleic acid molecules encoding such antibodies, vectors and host cells used in the production of the antibodies.Type: ApplicationFiled: June 28, 2012Publication date: May 1, 2014Applicants: KOBENHAVNS UNIVERSITET, RIGSHOSPITALETInventors: Peter Garred, Tina Hummelshoj Glue
-
Patent number: 8697384Abstract: The present invention relates to methods of diagnosing the presence of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above a reference level indicates the presence of a non-specific disease or disorder. The subject may suffer from a variety of diseases or disorders. The reference level may be a reference level obtained from healthy individuals or it may be a previous measurement obtained from the same subject. The present invention furthermore relates to a method for classifying the severity of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above or below one or more reference levels gives the severity of said non-specific disease or disorder. The present invention further relates to a kit and a device that may be used in the method of the present invention comprising means for measuring the level of YKL-40 in a sample; and means for comparing the measured level of YKL-40 with at least one reference level of YKL-40.Type: GrantFiled: January 22, 2009Date of Patent: April 15, 2014Assignees: Herlev Hospital, Hvidovre Hospital, RigshospitaletInventors: Julia Johansen, Stig Bojesen, Børge Grønne Nordestgaard, Hans Jørgen Nielsen, Ib Jarle Christensen
-
Publication number: 20140100419Abstract: The present invention relates to methods for improving the ability of spermatozoa to fertilize an egg in vitro and/or vivo, said method comprising providing a medium comprising active vitamin D (calcitriol) or analogs thereof, providing a sample of spermatozoa, and incubating said sample of spermatozoa with said medium. In addition, the invention relates to compositions comprising active vitamin D or analogs thereof for use in the treatment of infertility in a male or female subject.Type: ApplicationFiled: January 31, 2012Publication date: April 10, 2014Applicant: RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITALInventor: Martin Blomberg Jensen
-
Publication number: 20140044797Abstract: The present invention relates to the novel use of prostacyclin analogs for prevention and/or treatment of capillary leakage during surgery. The treatment of the present invention mediates discrete or minimal effects on haemostasis and vasodilation. Thus the present invention provides prostacyclin and analogs thereof for treatment which prevents capillary leakage while minimizing the risk of bleeding. The present invention further provides pharmaceutical compositions and kits of parts comprising prostacyclin or analogs thereof, and methods for treatment.Type: ApplicationFiled: March 30, 2012Publication date: February 13, 2014Applicant: RigshospitaletInventors: Par Johansson, Sisse Rye Ostrowski
-
Publication number: 20140046276Abstract: The present invention pertains to use of sodium diacetate (NaHAc2) as an antimicrobial agent against bacteria growing in biofilms. The aspects of the invention include a wound care product comprising sodium diacetate, a kit comprising a wound care product, and a method of treating an infected wound.Type: ApplicationFiled: April 18, 2012Publication date: February 13, 2014Applicants: RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITAL, BISPEBJERG HOSPITAL, DANMARKS TEKNISKE UNIVERSITETInventors: Thomas Bjarnsholt, Klaus Kirketerp-Moller, Michael Christian Givskov
-
Patent number: 8580520Abstract: The present invention relates to gastrointestinal cancers and methods for selecting a treatment for said gastrointestinal cancer in a subject. The present invention further relates to a methods of diagnosing the presence of and/or classifying the severity of a gastrointestinal cancer; together with methods for determining the effect of a therapy administered and/or the prognosis for a subject suffering from a gastrointestinal cancer, before, during or after administering the treatment. For all the methods applies that a determined level of YKL-40 above one or more reference levels indicates the treatment, the severity of the disease, the effect of the treatment and/or the prognosis of the subject. The reference level is typically a level obtained from healthy individuals or a level previously obtained from the same subject. The subject may suffer from any one or more gastrointestinal cancers, such as upper gastrointestinal cancers, and metastatic colorectal cancer.Type: GrantFiled: September 14, 2009Date of Patent: November 12, 2013Assignees: Herlev Hospital, Rigshospitalet, Hvidovre HospitalInventors: Julia Sidenius Johansen, Nicolai Aagaard Schultz, Benny Vittrup Jensen, Stig Bojesen, Børge Grønne Nordestgaard, Hans Jørgen Nielsen, Ib Jarle Christensen
-
Publication number: 20130274133Abstract: The present invention relates to a method for predicting the response of patients to treatment with Interleukin-6 Receptor (IL6R) inhibitors, such as antibodies directed against the IL6R. The method comprises the analysis of one or more genetic variations, in particular single nucleotide polymorphisms, in or associated with the Interleukin-6 Receptor gene. The present invention further relates to a kit for use in predicting the response of patients to treatment with IL6R inhibitors, such as Tocilizumab. The patients suffers from rheumatoid arthritis.Type: ApplicationFiled: September 30, 2011Publication date: October 17, 2013Applicant: RIGSHOSPITALETInventors: Claus Henrik Nielsen, Christian Enevold
-
Publication number: 20130261177Abstract: The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.Type: ApplicationFiled: September 30, 2011Publication date: October 3, 2013Applicant: RIGSHOSPITALETInventors: Pär Johansson, Sisse Rye Ostrowski
-
Publication number: 20130093866Abstract: The present invention relates to a system and a method for monitoring/tracking the movement of an object in a location which is difficult to access, such as the movement of a patient in a clinical MRI scanner. This is achieved by an optical motion tracking system for determining the movement of an object at least partly located in a volume of difficult access and/or at least partly located in an electromagnetic field, said system comprising a borescope for imaging a pattern on the object or a surface part of the object with a camera, said pattern or surface part located adjacent to a distal end of the borescope and said camera attached to a proximal end of said borescope, and image processing means for calculating the movement of said pattern or surface part relative to the distal end of the borescope based on a plurality of frames/images captured by the camera.Type: ApplicationFiled: March 18, 2011Publication date: April 18, 2013Applicant: RIGSHOSPITALETInventors: Anders Ohlhues, Carsten Thomsen
-
Publication number: 20130060208Abstract: The present invention relates to wound care products, devices and methods incorporating acetic acid for the treatment of bacterial infections, in particular bacterial biofilm infections. In particular it relates to a wound care product comprising acetic acid, wherein the product comprises at least one further antibacterial compound; a delivery system comprising a container connected to a means of delivery which is connected to a pad, wherein said container comprises a composition comprising acetic acid and said pad comprises a self-adhesive material; a kit comprising a dressing and an adhesive membrane, wherein the dressing comprises a composition comprising acetic acid; a method of treating a wound comprising a) applying acetic acid to the wound and b) applying a negative pressure to the wound.Type: ApplicationFiled: December 21, 2010Publication date: March 7, 2013Applicants: RIGSHOSPITALET, COPENHAGEN UNIVERSITY HOSPITAL, BISPEBJERG HOSPITAL, DANMARKS TEKNISKE UNIVERSITETInventors: Michael Christian Givskov, Thomas Bjarnsholt, Klaus Kirketerp-Møller
-
Publication number: 20130045890Abstract: The present invention relates generally to a method for predicting the fertility potential in a male mammal. In particular it relates to a method for predicting the fertility potential in a male mammal by determining the expression of at least one protein of the vitamin D metabolising machinery in a semen sample. The expression level of the at least one protein of the vitamin D metabolising machinery is then indicative of the fertility potential of the subject. An object of the present invention relates to a method, which can predict whether the semen quality is sufficient to achieve pregnancy spontaneously or if the couple should proceed to assisted reproduction or further investigation.Type: ApplicationFiled: May 3, 2011Publication date: February 21, 2013Applicant: Rigshospitalet Copenhagen University HospitalInventors: Martin Blomberg Jensen, John Erik Nielsen, Niels Jorgensen, Kristian Almstrup, Henrik Leffers
-
Publication number: 20120282285Abstract: The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to anti-bodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.Type: ApplicationFiled: July 16, 2010Publication date: November 8, 2012Applicants: RIGSHOSPITALET, SYDDANSK UNIVERSITET, KØBENHAVNS UNIVERSITETInventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Publication number: 20120101004Abstract: The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement acType: ApplicationFiled: June 9, 2010Publication date: April 26, 2012Applicants: Kobenhavns Universitet (University of Copenhagen), RigshospitaletInventors: Peter Garred, Christian Honoré